Introduction
Approximately 30-70% of people undergoing allogeneic hematopoietic stem cell transplantation (HCT) for hematologic malignancies can anticipate experiencing acute and/or chronic graft-versus-host disease (GVHD). 1 The physical consequences depend on the severity of GVHD, but moderate to severe organ system involvement is associated with substantial medical morbidity and mortality. [2] [3] [4] Functional status and quality of life (QOL) measurements are two ways of assessing morbidity from the patient's perspective. Functional status refers to what people can actually accomplish in their daily activities, whereas QOL is a broader concept that also incorporates impact of the limitations. While there is a great deal of ongoing work to prevent and treat GVHD, documentation of the impact of acute and chronic GVHD on functional status and QOL has received less attention. Most prior work measuring the impact of GVHD on patients has been cross-sectional and not assessed people at structured time points, including before transplantation. 5, 6 In this study, we used a longitudinal study design to measure the impact of acute and chronic GVHD on QOL and functional status.
As acute and chronic GVHD are highly correlated, 7 we also explored whether we could separate the relative contributions of acute and chronic GVHD to post-HCT QOL and functional status.
Materials and methods

Subjects
Patients undergoing allogeneic HCT between November 1999 and January 2004 were eligible to participate. The Dana-Farber/Harvard Cancer Center Institutional Review Board approved the protocol.
Disease status was categorized at the time of study enrollment into three groups. Good risk patients were those with acute leukemia in first complete remission, stable phase chronic myeloid leukemia, early myelodysplastic syndrome (refractory anemia) or aplastic anemia. Poor risk patients were in relapse or had refractory disease. All other patients were considered of intermediate risk.
The specific conditioning regimen and graft manipulation, if any, was according to protocol requirements and attending physician or patient preference. Details of the transplantation regimens and GVHD prophylaxis have been published previously. [8] [9] [10] [11] [12] Study methods Self-reported QOL, functional status and chronic GVHD symptom data were collected as part of an ongoing prospective study of HCT recipients. Patients scheduled for HCT were mailed a cover letter explaining the study, an opt-out card, the pre-transplantation survey and a selfaddressed, stamped envelope. Because this was a minimal risk study, written informed consent was not required as return of the survey indicated implied consent. At 6 and 12 months post transplantation, survivors were again mailed surveys and self-addressed, stamped envelopes. Only one attempt was made to contact subjects at each time point. Patients who opted out of the study were not contacted again.
Self-administered surveys include the Short Form 12 (SF12) of the Medical Outcomes Study version 1 13 and the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT). [14] [15] [16] The SF-12v1 is a 12-item, brief, generic functional assessment that allows comparison with other patient populations suffering from nononcologic diseases. The two composite scales, a physical functioning (PCS12) and mental functioning (MCS12), were calculated. Scores are normalized so that a score of 50 with a standard deviation of 10 is equivalent to the general United States population. Higher scores indicate better functioning. The correlation between the SF12 and full SF36 summary scores is 0.91. 13 The FACT-BMT is a validated, oncology-specific, QOL instrument. It has 37 items and is comprised of four core scales: physical, social, emotional and functional, and includes a BMT-specific module capturing issues, especially pertinent to HCT patients. The trial outcome index (TOI) of the FACT-BMT is a composite of the physical, functional and transplantation-specific subscales that is meant to capture domains, particularly sensitive to the effects of different medical treatments. The TOI does not include the social and emotional subscales. We elected to use the TOI because our prior work showed a lack of sensitivity for the social and emotional subscales to differing severity of chronic GVHD. 17 Higher scores indicate better QOL and a difference of 5-7 points on the TOI has been accepted as clinically meaningful in other cancer populations. 18 Over the time period of this study, different versions of the survey were administered. All patients received surveys that included the FACT-BMT, but the SF12 was not included (April 2001-June 2001) (resulting in missing data for five patients).
Biostatistical analysis
To be included in the analysis, patients had to have a baseline survey and at least one follow-up survey at 6 or 12 months that included the TOI. Patients were divided into three groups according to acute and chronic GVHD: no grade II-IV acute and no chronic GVHD (NN), no grade II-IV acute GVHD but mild, moderate or severe chronic GVHD (NY), and both grade II-IV acute and mild, moderate or severe chronic GVHD (YY). Six patients with grade II-IV acute GVHD but no chronic GVHD were excluded from the analysis. Characteristics of the three subgroups are reported descriptively and compared by Kruskal-Wallis and Cochran-Mantel-Haenszel testing as appropriate.
The self-reported instruments were scored according to the methods recommended by the developers. No imputation methods were used for missing data, and each subscale was analyzed separately. It is notable that SF12 scores cannot be calculated if any item is missing in contrast to the TOI, that requires that at least half of items be answered in each section.
Pairwise and overall P-values in the tables derive from linear models with adjustment for clinical characteristics (patient age, receipt of total body irradiation, myeloablative versus non-myeloablative conditioning, related versus unrelated donors, disease risk, donor-patient sex matching, self-reported Eastern Cooperative Oncology Group (ECOG) performance status, stem cell source and relapse). All two-way P-values were adjusted for multiple testing using the Bonferroni correction, and only P-values o0.05 are reported numerically. Repeated measures analysis using PROC MIXED in SAS was used to adjust for serial assessments and clinical characteristics. Relapse was defined as hematologic, cytogenetic or clinical relapse and modeled as a time-varying covariate.
Results
A total of 96 subjects who provided a survey before transplantation and at least one follow-up survey at 6 or 12 months was included in this analysis. Subjects were divided into three groups to allow exploration of the differential impact of acute (grade II-IV) and chronic GVHD on post-HCT QOL: 31 (32% NN) experienced neither acute nor chronic GVHD, 37 (39% NY) had no acute GVHD but developed chronic GVHD and 28 (29% YY) experienced both acute and chronic GVHD. Six patients who experienced acute GVHD but no chronic GVHD were excluded from the analysis, as this group was too small for meaningful conclusions. Characteristics of participants are displayed in Table 1 . Baseline clinical characteristics and pre-HCT QOL scores were similar among the three groups. At 6 months, 80/96 survivors (83%) returned their surveys. At 12 months, 73/88 survivors (83%) returned a survey. Table 2 shows reasons for missing data. Table 3 shows pre-transplantation PCS12, MCS12 and TOI scores and the association of each GVHD group with longitudinal QOL. At 6 and 12 months, PCS12 and MCS12 proved to be fairly insensitive to the occurrence of acute and/or chronic GVHD. In contrast, the TOI provided good discrimination at 6 months between those with and without acute GVHD (P3 ¼ 0.01) and detected differences at 12 months between those with neither acute nor chronic GVHD and those with both (P2 ¼ 0.006). The Figure 1 Table 2 for details. P1, P2, P3, and overall P are from linear models with adjustment for clinical covariates and multiple testing for pairwise comparisons.
plots the mean TOI scores over time by group. At 6 months, acute GVHD is correlated with TOI score (YY 56.2 versus NN/NY mean 66.4, P ¼ 0.006), whereas at 12 months, chronic GVHD shows the strongest association (NY/YY mean 64.7 versus NN 76.8, P ¼ 0.008). Thus, it appears that chronic GVHD is independently associated with scores on the TOI at 12 months, independent of prior acute GVHD.
Multivariate longitudinal linear regression modeling adjusting for baseline characteristics (age, ECOG performance status pre-HCT, patient-donor sex matching, disease risk, total body irradiation, donor relationship, graft source and type of conditioning regimen) confirmed the association of acute and/or chronic GVHD with subsequent TOI (P ¼ 0.004). Relapse was also significantly associated with lower TOI (P ¼ 0.001). Time and the time by GVHD interaction were significant at Po0.05, but other variables were not significantly associated with TOI scores.
PCS12 and MCS12 were not associated with the occurrence of acute or chronic GVHD either in the analysis of raw scores or in multivariable modeling. In contrast, relapse was significantly associated with PCS12 at 6 months (P ¼ 0.02) and 12 months (P ¼ 0.03).
Discussion
In summary, both grades II and IV acute and chronic GVHD are associated with worse QOL after allogeneic HCT as measured by the TOI of the FACT-BMT. Patients who experience acute GVHD have a measurable decline in their QOL, whereas patients with no acute GVHD have stable QOL over the first 6 months after HCT. We hypothesize that residual effects of acute GVHD, or more likely, the toll taken on the patient from the extra hospitalization, infectious complications or need for higher doses of immunosuppressive medications influences reported QOL at 6 months post transplantation. However, these adverse effects seem to be largely dissipated at 12 months and QOL improves unless a patient develops chronic GVHD. Unfortunately, we were not able to explore this finding further as the YN group (patients who experienced acute GVHD but not chronic GVHD) was too small for meaningful analysis.
Although acute and chronic GVHD are highly correlated, the effects of acute and chronic GVHD on selfreported QOL appear to be independent. This is not surprising as the time frame of onset and resolution, organ manifestations and perceived implications for prognosis are very different even though the treatments may be the same. The TOI appears better able to discriminate between patients who did or did not experience acute or chronic GVHD than the SF12, confirming a prior report. 19 We hypothesize that the greater sensitivity of the TOI to GVHD may be owing to the emphasis of the FACT-BMT on oncology concerns and the impact of symptoms on QOL, rather than the SF12's orientation toward general functional measures.
Many cross-sectional studies have reported an association between acute and chronic GVHD and worse QOL, but few have quantified the differences between those with and without GVHD. 5, 6, [20] [21] [22] [23] [24] [25] Other studies have not found an association between GVHD and QOL, although this may be explained by smaller sample sizes or the instruments used. [26] [27] [28] Syrjala et al. 29 found that chronic GVHD was associated with depression but not physical limitations. McQuellon et al. 15 who developed the FACT-BMT and recommended the TOI as an endpoint, did not find an association between GVHD and QOL in their study.
We recognize a number of limitations to our study. First, results are from a single institution and reflect participation of a subset of patients undergoing allogeneic transplantation. As we required a completed baseline survey and at least one post transplantation survey (requiring survival to at least 6 months), many patients who partially participated were excluded. Nevertheless, our results should allow valid conclusions when differences are found among the three groups tested. Second, patients received heterogeneous conditioning regimens, GVHD prophylaxis regimens and treatments for any GVHD that did develop. While we were able to control for some of these differences in the multivariable modeling, others were not captured in our database and could also contribute to observed differences. However, on a positive note, our ability to draw strong conclusions in the face of population heterogeneity support use of FACT-BMT to study the QOL impact of GVHD in diverse clinical settings. Finally, clinical characteristics between our three groups failed to recapitulate risk factors reported in the literature, such as older age and peripheral blood grafts in patients with chronic GVHD. This could reflect the smaller number of patients in our study compared to clinical epidemiology studies or it could reflect our requirement that patients survive at least 6 months and provide at least one follow-up survey to be evaluable.
Relapse was associated with worse QOL at 6 and 12 months, but we did not analyze other causes of diminished QOL and higher symptom burden post-HCT, including other transplant complications and response of GVHD to therapeutic interventions. We did not have adequate clinical data or patient numbers to evaluate many other potential contributors to poor QOL. It is reasonable to assume that unremitting GVHD, significant infections and organ toxicity also decrease QOL. However, infections and organ toxicity may be directly related to GVHD or its treatment, factors that would greatly complicate such an analysis.
While most clinical trials of acute and chronic GVHD prophylaxis and treatment have purely medical or laboratory end points, we suggest that QOL is also a valid and important measure of successful GVHD prevention and treatment. Whether there are other interventions that could improve functional status and QOL, independent of GVHD prophylaxis and therapy, also deserves study.
